Bespak

Activities: Packaging Drug Delivery Pharmaceutical

Trending Articles

  1. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  2. Lonza expands bioconjugation capabilities for ADC manufacturing at Visp site The CDMO's facility will double its bioconjugate manufacturing capacity with two 1,200 L manufacturing suites
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  5. Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Sustainability

Bespak and Orbia Fluor & Energy Materials partner to create climate-friendly inhalers

The two companies will create pMDIs with an optimised sustainability profile with Orbia's low global warming potential (GWP) propellant, Zephex 152a
Manufacturing

Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs

Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Manufacturing

Bespak reaches milestone in pMDI manufacturing facility expansion

The company has fitted a novel manufacturing line that can produce pMDI products at its Holmes Chapel, UK site
Sustainability

Bespak separation from Recipharm to focus on the transition to low GWP pMDIs

The spin-out has created a global CDMO focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation
Sustainability

DevPro Biopharma and Bespak complete early studies for novel sustainable albuterol inhaler

The novel formulation exhibits a low global warming potential (GWP) and shows comparable performance to Ventolin HFA
Sustainability

Bespak and H&T Presspart collaborate to advance transition to low-GWP propellants in pMDIs

Partnership will provide GMP filling capabilities and development support for clinical trial programmes with low GWP propellants
Sustainability

Sustainability and innovation in the complex combination therapy sector

The patient and commercial benefits of bringing new drugs to market in the shortest possible time are well recognised; potential methodologies to reduce the development cycle and accelerate drug product approvals are constantly being explored. As a result, other targets, including the environmental efficacy of a therapy, have traditionally been a distant, secondary objective. Bespak's Jay Bhogaita, Business Director, reports
Subscribe now